The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,170.00
Ask: 12,172.00
Change: -76.00 (-0.62%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,168.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-AstraZeneca, U.S. agree 500,000 more supplies of COVID-19 antibody cocktail

Tue, 16th Mar 2021 07:23

* Extended U.S. deal for $205 mln, total value now at $726
mln

* Overall supply deal contingent on approval of treatment,
AZD7442

* Deal comes as AZ grapples with COVID-19 vaccine
suspensions
(Writes through with new details, background)

By Pushkala Aripaka

March 16 (Reuters) - AstraZeneca will supply up to
half a million extra doses of its experimental antibody-based
COVID-19 combination therapy to the United States, in a bright
spot for the company after more governments suspended use of its
vaccine over safety fears.

The antibody therapy, which has yet to be approved by U.S.
regulators, is designed to treat the disease rather than prevent
it like the vaccine, which several countries have stopped using
while reports of blood clots in some people are investigated.

The Anglo-Swedish drugmaker said on Tuesday the $205 million
U.S. extension for 500,000 antibody doses builds on a contract
agreed with government agencies in October for initial supplies
of 200,000 doses of the antibody cocktail, AZD7442.

The treatment is a combination of two monoclonal antibodies,
London-listed AstraZeneca said, adding that the new agreement is
contingent on an emergency use approval by the U.S. Food and
Drug Administration.

"The US Government's support is critical in helping
accelerate the development of AZD7442," AstraZeneca Chief
Executive Pascal Soriot said.

The total value of the deal now stands at $726 million for
up to 700,000 doses. AZD7442 is being evaluated in late-stage
trials, the company said, adding that it currently does not
expect any changes to its 2021 forecasts due to the deal.

While AstraZeneca has undergone a rollercoaster ride with
its COVID-19 vaccine, it has been working on developing new
treatments and repurposing its existing drugs to prevent and
treat coronavirus infections.

Monoclonal antibodies, such as the ones being used in
AZD7442, are synthetically manufactured copies of the human
body's natural infection-fighting proteins, and are already
being used to treat some types of cancers.

A series of issues have bogged down the drugmaker's vaccine
rollout: including pauses in trials, questions over the most
effective dosing, and supply problems. Share gains from optimism
around the cheap and easy-to-ship shot have also been decimated.

On Tuesday, the stock was up 1.5% at 7,090 pence in early
trading. At its peak in July last year, the company hit 10,120
pence.

(Reporting by Pushkala Aripaka in Bengaluru, Editing by Sherry
Jacob-Phillips and Philippa Fletcher)

More News
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.